Merck (MRK) Q3 2026 Earnings Call Transcript

Merck reported Q3 2026 revenue of $18.1 billion, up 5% year over year, and non-GAAP EPS of $2.49; it raised the midpoint of 2026 revenue guidance to $66.8–$67.3 billion and EPS guidance to $2.77–$2.82. Management expects more than $2 billion of 2027 revenue headwinds from generic competition and loss of exclusivity for BRIDION, Januvia-family products, and Adempas, partly offset by new-product growth. The company also cited progress in its pipeline and launches, while remaining on track for approximately $3 billion in 2026 share repurchases.

Analysis

The near-term issue is earnings quality, not headline growth: U.S. purchase timing and channel inventory supported the quarter, with part of the vaccine benefit explicitly rolling into 2027. Keytruda and WINREVAIR timing reverses in Q4, while the remaining vaccine timing benefit adds another headwind next year. That compounds the disclosed >$2B generic/LOE drag, moderating Keytruda growth, and higher R&D and launch spending. The unusually low Q3 tax rate also makes the quarter a poor run-rate for EPS; track the full-year tax guide and underlying operating performance rather than annualizing this print.

The offset is a portfolio transition, not yet proof of earnings replacement. QLEX may defend convenience and retain U.S. administration share, but does not itself remove Keytruda molecule-level LOE risk; European injunctions are a modest near-term volume issue by management’s account, with legal outcome and U.S. freedom to operate worth monitoring. WINREVAIR, LIPFENDRA, and sac-TMT broaden the growth bridge, but launch uptake and trial results must translate into durable sales. Sac-TMT’s June 2027 FDA decision and further pipeline readouts are meaningful 6–18 month catalysts; melanoma vaccine results offer Moderna (MRNA) partnership optionality, but the transcript does not disclose economics sufficient to underwrite MRNA revenue impact.

Contrarian point: the LOE “hill” framing may understate a period when mature-product erosion, vaccine demand weakness, and reinvestment pressure arrive together. Conversely, generic erosion is visible and may already be reflected in MRK expectations; absent valuation and consensus data, there is no basis to call the stock mispriced. Falsifiers for a cautious near-term view include sustained organic growth after inventory reversals, new-product sales replacing legacy erosion, or better-than-guided 2027 operating leverage.

Key Decisions for Investors

• Avoid chasing MRK on the quarter; defer incremental additions until Q4 confirms the Keytruda/WINREVAIR inventory unwind and the next outlook clarifies how much vaccine timing and underlying demand affect 2027. Reassess if organic growth remains firm after those reversals.
• For a 1–3 month horizon, keep MRK exposure neutral-to-cautious rather than initiating an unhedged short: the visible generic headwinds argue against extrapolating the 2026 run rate, but pipeline catalysts and missing valuation/consensus data make a directional short asymmetric. Trim the thesis if new-product growth demonstrably offsets legacy declines.
• Treat sac-TMT’s June 15, 2027 PDUFA date and upcoming clinical readouts as catalyst alerts, not booked growth. Revisit MRK sizing on regulatory outcomes and evidence of commercial uptake; failure to convert positive data into approval or launches would weaken the post-Keytruda bridge.
• Do not trade MRNA solely on the melanoma vaccine read-through. Verify collaboration economics, development cost sharing, and potential launch timing before assigning material earnings value; the article provides none of those inputs.